Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyrroline-5-carboxylate reductase 3 (PYCR3) is a cytoplasmic enzyme that catalyzes the final step of proline biosynthesis, converting pyrroline-5-carboxylate (P5C) to L-proline using NAD(P)H as a cofactor[2][7]. PYCR3 belongs to the pyrroline-5-carboxylate reductase family of oxidoreductases and is primarily involved in the biosynthesis of proline from ornithine[1][2]. The enzyme plays an important role in amino acid metabolism and may influence cell growth and stress responses. Mutations or dysregulation in PYCR3 are associated with rare metabolic disorders such as leukodystrophy (hypomyelinating, type 10) and cutis laxa (autosomal recessive, type IIB), and the gene is expressed in various human cancers[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyrroline-5-carboxylate reductase 3 (PYCR3).